PKTX

Protokinetix (QB) Stock Price

0.10
0.00 (0.0%)
0.10
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Protokinetix Inc (QB) PKTX OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.10 0.00 0.00 0.00 0.10 08:46:58
Bid Price Ask Price Spread Spread % News
0.0951 0.10 0.005 5.0% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.10 USD

Protokinetix (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 27.76M 277.62M 147.03M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
51.69k $ - 0.00% - -

more financials information »

Protokinetix (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PKTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.1090.1090.080.0909256122,381-0.009-8.26%
1 Month0.130.130.080.103964779,559-0.03-23.08%
3 Months0.1010.14020.080.106548771,604-0.001-0.99%
6 Months0.0910.220.080.142742595,9810.0099.89%
1 Year0.252850.2890.080.143919693,320-0.15285-60.45%
3 Years0.06790.320.030.1209016102,2260.032147.28%
5 Years0.06420.320.02010.1015199109,8830.035855.76%

Protokinetix (QB) Description

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP) that enhance both engraftment and protection of transplanted cells, tissues and organs used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trial. Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. In addition, we are studying the potential impact on several cancer therapies.


Your Recent History
USOTC
PKTX
Protokinet..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.